Condition: Metastatic Urothelial Carcinoma · Sponsor: Astellas Pharma Global Development, Inc.
This study is for Indian adults in India who have cancer in the bladder lining (urothelial cancer). Their cancer is advanced or has spread to other parts of the body. Enfortumab vedotin is a treatment for this type of cancer. The main aim of the study is to confirm the safety of enfortumab vedotin in Indian adults with urothelial cancer. During the study, people will receive enfortumab vedotin. The study treatment will be given to people slowly through a tube into a vein. This is called an infusion. People will receive 3 separate infusions of enfortumab vedotin in each 28-day (4 weeks) treatment cycle. People visit their study clinic for health-checks several times during and after they receive enfortumab vedotin.
This description comes directly from the study's public registry record.
Astellas Pharma Global Development, Inc. · 800-888-7704 · astellas.registration@astellas.com
Always discuss trial participation with your own doctor first.
| Site IN91013 | Patna, Bihar, India | Recruiting |
| Site IN91015 | Kochi, Kerala, India | Recruiting |
| Site IN91004 | Mumbai, Maharashtra, India | Recruiting |
| Site IN91016 | New Delhi, National Capital Territory of Delhi, India | Recruiting |
| Site IN91017 | Dumas, Surat, India | Recruiting |
| Site IN91007 | Vellore, Tamil Nadu, India | Recruiting |
| Site IN91005 | Varanasi, Uttar Pradesh, India | Recruiting |
| Site IN91006 | Kolkata, West Bengal, India | Recruiting |
| Site IN91012 | Ahmedabad, India | Recruiting |
| Site IN91010 | Bhubaneswar, India | Recruiting |
| Site IN91008 | Mumbai, India | Recruiting |
| Site IN91009 | Nagpur, India | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06862219